Pharma Bio Services (PBSV)
OTHER OTC:PBSV
PBSV Stock Chart & Stats
$0.54
-$0.14(-25.27%)
At close: 4:00 PM EST
$0.54
-$0.14(-25.27%)
Day’s Range― - ―
52-Week Range$0.35 - $1.36
Previous CloseN/A
Volume2.02K
Average Volume (3M)2.53K
Market Cap
$11.22M
Enterprise Value-$5.75B
Total Cash (Recent Filing)$10.56B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)103.6
Beta-0.13
Next Earnings
Jun 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding22,901,691
10 Day Avg. Volume1,930
30 Day Avg. Volume2,531
Financial Highlights & Ratios
PEG Ratio1.42
Price to Book (P/B)1.04
Price to Sales (P/S)1.38
P/FCF Ratio-55.94
Enterprise Value/Market Cap-512.61
Enterprise Value/Revenue-2.92
Enterprise Value/Gross Profit-9.98
Enterprise Value/Ebitda18.39K
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.11
Revenue Forecast (FY)$12.00M
Bulls Say, Bears Say
Bulls Say
Strong Recent Revenue GrowthA 116% TTM revenue surge signals meaningful demand expansion or contract gains. Durable higher revenue provides a platform to scale fixed-cost absorption and supports longer-term margin improvement if growth persists and the company sustains customer retention and delivery capacity over the next several quarters.
Very Low LeverageNear-zero debt materially reduces financial risk and interest burden, giving the company flexibility to fund operations, absorb losses, or pursue strategic investments without immediate refinancing pressure. This balance-sheet strength is a durable stabilizer in downturns.
Healthy Gross MarginA ~29% gross margin indicates favorable unit economics in core services, leaving room to cover SG&A and R&D. If management controls operating expenses, this margin level supports potential path to sustainable profitability as revenue scales, making gross margin a lasting structural advantage.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow erode liquidity and limit the company's ability to self-fund growth or capex. Over months, this forces dependence on external financing or equity, increases execution risk on strategic plans, and can constrain investment in sales or product development.
Weak Operating ProfitabilityNegative EBIT/EBITDA and near-zero net margins show core operations currently fail to generate operating profits. This reduces return-on-invested-capital prospects and makes the business vulnerable until cost structure is tightened or revenue mix shifts to higher-margin offerings.
Minimal/negative Returns On EquityA large equity base paired with minimal or negative ROE indicates inefficient capital use and poor shareholder returns. Over the medium term, persistent weak ROE can limit investor confidence and reduce capital available for strategic initiatives unless operational performance meaningfully improves.
Pharma Bio Services News
PBSV FAQ
What was Pharma Bio Services’s price range in the past 12 months?
Pharma Bio Services lowest stock price was $0.34 and its highest was $1.36 in the past 12 months.
What is Pharma Bio Services’s market cap?
Pharma Bio Services’s market cap is $11.22M.
When is Pharma Bio Services’s upcoming earnings report date?
Pharma Bio Services’s upcoming earnings report date is Jun 17, 2026 which is in 82 days.
How were Pharma Bio Services’s earnings last quarter?
Pharma Bio Services released its earnings results on Mar 17, 2026. The company reported $0.001 earnings per share for the quarter, beating the consensus estimate of $0 by $0.001.
Is Pharma Bio Services overvalued?
According to Wall Street analysts Pharma Bio Services’s price is currently Overvalued.
Does Pharma Bio Services pay dividends?
Pharma Bio Services pays a Notavailable dividend of $0.075 which represents an annual dividend yield of N/A. See more information on Pharma Bio Services dividends here
What is Pharma Bio Services’s EPS estimate?
Pharma Bio Services’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pharma Bio Services have?
Pharma Bio Services has 22,901,691 shares outstanding.
What happened to Pharma Bio Services’s price movement after its last earnings report?
Pharma Bio Services reported an EPS of $0.001 in its last earnings report, beating expectations of $0. Following the earnings report the stock price went down -1.042%.
Which hedge fund is a major shareholder of Pharma Bio Services?
Currently, no hedge funds are holding shares in PBSV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pharma Bio Services
Pharma-Bio Serv, Inc. operates as a compliance and technology transfer services consulting firm. The company provides compliance consulting services to the pharmaceutical, chemical, biotechnology, medical device, cosmetic, food industries, and allied products companies in Puerto Rico, the United States, Europe, and Brazil. Its technical consulting services comprise regulatory compliance, validation, technology transfer, engineering, project management, and process support. The company was founded in 1993 and is headquartered in Dorado, Puerto Rico.
Technical Analysis
Zhongchao
―
Healthcare Triangle
―
VSee Health
―
Aclarion, Inc.
―
BullFrog AI Holdings, Inc.
―